Funded Startups in Gothenburg
In this Gothenburg-focused set of 35 funded startups, the largest disclosed round is Pagero’s $74M Post-IPO Debt on 2022-05-09, which dwarfs the next-large…
In this Gothenburg-focused set of 35 funded startups, the largest disclosed round is Pagero’s $74M Post-IPO Debt on 2022-05-09, which dwarfs the next-largest disclosed amounts ($19M for Minna Technologies on 2021-01-14 and $20K–$12M for most other disclosed rounds). The disclosed amounts also show a clear skew toward smaller checks: several entries sit in the $540K–$3M range (e.g., Arkeon Technologies $690K on 2026-06-11; Observe Medical $2M on 2026-03-04; Cetasol $3M on 2025-09-28), while only a handful reach $5M+ (e.g., Thunderful Group $5M on 2025-10-03; Mimbly $4M on 2025-11-07).
Date-wise, the listing runs from 2020-08-20 (Hiber) up to 2026-06-25 (Anferra), with the most recent entries clustering in mid-2026: multiple rounds appear from 2026-06-04 through 2026-06-25 (Smoltek $20K on 2026-06-04; Arkeon Technologies $690K on 2026-06-11; Anferra undisclosed on 2026-06-25). Sector- and stage-wise, “Series Unknown” appears in 17 of 35 rows, and “undisclosed” appears in 6 of 35 rows, while healthcare and biotech repeatedly show up as adjacent clusters (e.g., Verigraft AB $12M on 2026-03-12; Observe Medical $2M on 2026-03-04; MucoLife Therapeutics $30K on 2024-09-06; Fluicell $20K on 2024-10-17).
Most recent rounds
35 shownRelated listings
Frequently asked
What outlier stands out on deal size in the Gothenburg list, and how does it compare to the rest of the disclosed rounds?
Pagero’s $74M Post-IPO Debt on 2022-05-09 is the clear size outlier, far above the next-largest disclosed amounts in the table (Minna Technologies $19M on 2021-01-14, and Verigraft AB $12M on 2026-03-12). Most other disclosed checks fall well below that—frequently in the hundreds of thousands to a few million (e.g., Arkeon Technologies $690K on 2026-06-11; Observe Medical $2M on 2026-03-04).
Do recent rounds cluster into a narrow time window near the top of the table?
Yes. Several entries fall within late June 2026, including Smoltek on 2026-06-04 ($20K), Arkeon Technologies on 2026-06-11 ($690K), and Anferra on 2026-06-25 (undisclosed). More broadly, 2024–2026 contains repeated seed and mid-size disclosed rounds, such as Cetasol $3M on 2025-09-28 and DREV $3M on 2025-11-04.
How often are amounts or round stages missing, and does that limit comparisons?
Round stage is “Series Unknown” in 17 of 35 rows, and “undisclosed” amounts appear in 6 of 35 rows. This means deal-size ranking is only possible for disclosed amounts; for example, Anferra (2026-06-25) and PulPac (2026-02-23) are both present but cannot be placed by disclosed check size.
Which stage labels dominate, based on the rows shown?
“Series Unknown” is the most frequent stage label (17 of 35). Seed is repeatedly present as well (e.g., Arkeon Technologies $690K on 2026-06-11; DREV $3M on 2025-11-04; Cetasol $3M on 2025-09-28), while other labeled stages are less common, such as Pre-Seed (MucoLife Therapeutics $30K on 2024-09-06; RadChat $40K on 2023-06-15).
Is there an identifiable sector cluster, especially around healthcare/biotech?
Healthcare and biotech-adjacent entries recur across multiple years rather than being isolated. Examples include Verigraft AB (Biotechnology) $12M on 2026-03-12, Observe Medical (Health Care) $2M on 2026-03-04, Fluicell (Biotechnology) $20K on 2024-10-17, and MucoLife Therapeutics (Health Care) $30K on 2024-09-06, indicating repeated funding activity in life-science themes.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.